Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 08/02/2013) - Results from a phase III trial show that radium-223 dichloride (Xofigo®) improves overall survival in men with advanced prostate cancer that has spread to their bones compared with placebo.
Crizotinib Improves Progression-Free Survival in Some Patients with Advanced Lung Cancer
(Posted: 06/17/2013) - Results from an international phase III trial show that crizotinib (Xalkori®) substantially extends progression-free survival in previously treated patients with advanced lung cancer whose tumors have a specific genetic mutation.
Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer
(Posted: 02/07/2013, Updated: 06/02/2013) - Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an analysis of a large, randomized clinical trial.
Two Drugs that Hit One Target Show Efficacy against Metastatic Breast Cancer
(Updated: 04/30/2013) - Combining two drugs that target the HER2 protein, trastuzumab (Herceptin®) and pertuzumab, with chemotherapy is a new treatment option for women with HER2-positive metastatic breast cancer, according to results from a large clinical trial.
Women with Breast Cancer Micrometastases in Their Sentinel Lymph Nodes May Not Need Axillary Dissection
(Posted: 04/26/2013) - Results from a randomized clinical trial showed that women with breast cancer and only micrometastases in their sentinel lymph nodes who received axillary lymph node dissection had more side effects but no improvement in disease-free survival compared with women who had no further lymph node surgery.